RTC Dec Felicitas Koller and Eric Grogan

Similar documents
Quiz Adenocarcinoma of the distal stomach has been increasing in the last 20 years. a. True b. False

Case Scenario year-old white male presented to personal physician with dyspepsia with reflux.

Case Scenario 1. The patient has now completed his neoadjuvant chemoradiation and has been cleared for surgery.

ESOPHAGEAL CANCER AND GERD. Prof Salman Guraya FRCS, Masters MedEd

Aliu Sanni MD SUNY Downstate Medical Center August 16, 2012

Esophageal Cancer Staging Essentials: The New TNM Staging System (7th edition) and Clinicoradiologic Implications

SETTING Fudan University Shanghai Cancer Center. RESPONSIBLE PARTY Haiquan Chen MD.



Abstracting Upper GI Cancer Incidence and Treatment Data Quiz 1 Multiple Primary and Histologies Case 1 Final Pathology:

01/26/2010 GENERAL SURGERY ABSITE ANATOMY ANATOMY. Yvonne M. Carter, MD Georgetown University Medical Center. Layers. mucosa. squamous epithelium

7/20/2017. Esophageal Cancer: A Less Common But Deadly Cancer. Objectives. Disclosure Statement NYNPA Conference October Saratoga New York

COLLECTING CANCER DATA: STOMACH AND ESOPHAGUS

Gastric Cancer Histopathology Reporting Proforma

Tumours of the Oesophagus & Gastro-Oesophageal Junction Histopathology Reporting Proforma

Gastroesophageal reflux disease Principles of GERD treatment Treatment of reflux diseases GERD

Minimally Invasive Esophagectomy: OVERRATED!!! Sagar Damle UCHSC December 11, 2006

Controversies in management of squamous esophageal cancer

Management of Esophageal Cancer: Evidence Based Review of Current Guidelines. Madhuri Rao, MD PGY-5 SUNY Downstate Medical Center

The Learning Curve for Minimally Invasive Esophagectomy

Determining the Optimal Surgical Approach to Esophageal Cancer

Esophageal Cancer. Wesley A. Papenfuss MD FACS Surgical Oncology Aurora Cancer Care. David Demos MD Thoracic Surgery Aurora Cancer Care

THORACIC SURGERY: Dysphagia. Dr. Robert Zeldin Dr. John Dickie Dr. Carmine Simone. Thoracic Surgery Toronto East General Hospital

A Multidisciplinary Approach to Esophageal Dysphagia: Role of the SLP. Darlene Graner, M.A., CCC-SLP, BRS-S Sharon Burton, M.D.

A Proposed Strategy for Treatment of Superficial Carcinoma. in the Thoracic Esophagus Based on an Analysis. of Lymph Node Metastasis

8. The polyp in the illustration can be described as (circle all that apply) a. Exophytic b. Pedunculated c. Sessile d. Frank

9/18/2015. Disclosures. Objectives. Dysphagia Sherri Ekobena PA-C. I have no relevant financial interests to disclose I have no conflicts of interest

Surgical Problems in Proximal GI Cancer Management Cardia Tumours Question #1: What are cardia tumours?

Greater Manchester & Cheshire Guidelines for Pathology Reporting for Oesophageal and Gastric Malignancy

Minimally Invasive Esophagectomy- Valuable. Jayer Chung, MD University of Colorado Health Sciences Center December 11, 2006

Determining Resectability and Appropriate Surgery for Esophageal Cancer

AATS Focus on Thoracic Surgery: Minimally Invasive Esophagectomy: Are We Still Getting Better in 2017?

Endoscopic UltraSound (EUS) Endoscopic Mucosal Resection (EMR) Moishe Liberman Director C.E.T.O.C.

A916: rectum: adenocarcinoma

Molly Boyd, MD Glenn Mills, MD Syed Jafri, MD 1/1/2010

A218 : Esophagus cancer tissues. (formalin fixed)

Imaging in gastric cancer

Histopathology of Endoscopic Resection Specimens from Barrett's Esophagus

Exercise 15: CSv2 Data Item Coding Instructions ANSWERS

Colorectal Cancer Structured Pathology Reporting Proforma DD MM YYYY

ESOPHAGEAL CANCER. Dr. Paul Gardiner December 17, 2002 Discipline of Surgery Rounds

An Update: Lung Cancer

Esophageal Cancer: A Multimodality Approach to Detection and Staging

Pancreas Quizzes c. Both A and B a. Directly into the blood stream (not using ducts)

Mediastinal Staging. Samer Kanaan, M.D.

Gastric Cancer in a Young Postpartum Female. Kings County Hospital Center SUNY Downstate Case Conference May 24, 2012

11/21/13 CEA: 1.7 WNL

Surgical strategies in esophageal cancer

MEDIASTINAL STAGING surgical pro

WHO BENEFITS FROM ADJUVANT CHEMOTHERAPY RADIATION CHEMORADIATION? Dr. Paul Gardiner April 23, 2001 Discipline of Surgery Grand Rounds

Patient. Male 76 year old C.C: abdominal pain

Case Scenario 1 Worksheet. Primary Site C44.4 Morphology 8743/3 Laterality 0 Stage/ Prognostic Factors

North of Scotland Cancer Network Clinical Management Guideline for Non Small Cell Lung Cancer

Oesophageal Cancer: The Image after Surgery

Diagnosis and Preoperative Staging of Esophageal Cancer

Oesophageal Cancer: The Image after Surgery

Slide 1. Slide 2. Slide 3. Investigation and management of lung cancer Robert Rintoul. Epidemiology. Risk factors/aetiology

Minimally Invasive Esophagectomy

Esophagus Stomach 4/2/15

Hong Kong Society of Upper Gastrointestinal Surgeons CLINICAL MEETING 29 NOV 2012

Faculty Disclosure. Objectives. State of the Art #3: Referrals for Gastroscopy (focus on common esophagus problems) 24/11/2014

This form may provide more data elements than required for collection by standard setters such as NCI SEER, CDC NPCR, and CoC NCDB.

Esophageal Cancer. Source: National Cancer Institute

GALLBLADDER CANCER. Lidie M. Lajoie MD Downstate Surgery M&M July 21, 2011

Esophageal cancer: Biology, natural history, staging and therapeutic options

UCLA General Surgery Residency Program Rotation Educational Policy Goals and Objectives

National Oesophago-Gastric Cancer Audit New Patient Registration sheet Patients with Oesophageal High Grade Glandular Dysplasia

Robotic Surgery for Esophageal Cancer

Gastric Cancer Staging AJCC eighth edition. Duncan McLeod Westmead Hospital, NSW

Limited en bloc Resection of the Gastroesophageal Junction with Isoperistaltic Jejunal Interposition

Esophageal Diverticulum. Ahmed Hozain, PGY III Kings County Hospital University Hospital of Brooklyn, Surgery Grand Rounds May 18 th, 2017

Carcinoma of the Renal Pelvis and Ureter Histopathology

MECHANISMS OF HUMAN DISEASE: LABORATORY SESSIONS GASTROINTESTINAL (GI) PATHOLOGY LAB #1. January 06, 2012

Navigators Lead the Way

MPH Quiz. 1. How many primaries are present based on this pathology report? 2. What rule is this based on?

History. Prevalence at Endoscopy. Prevalence and Reflux Sx. Prevalence at Endoscopy. Barrett s Esophagus: Controversy and Management

Esophagus and Esophagogastric Junction

Medical Science DR JITENDRA TADGHARE DR BEENA VAIDYA DR MILAN SNEHKUNJ DR HARISINH PARMAR DR GAURAV BAVADIYA DR DEEP PARMAR.

SEER Summary Stage Still Here!

This form may provide more data elements than required for collection by standard setters such as NCI SEER, CDC NPCR, and CoC NCDB.

Surgery for Gastric and Oesophageal Cancer

A 16 yr old boy with aggressive ca esophagus. DR Ayunga A.O Physician-Garisa PGH Associate Faculty Lecturer-UON Afya Bora Fellow in Global Health

Esophageal Cancer. What is esophageal cancer?

Role of Surgery in Management of Non Small Cell Lung Cancer. Dr. Ahmed Bamousa Consultant thoracic surgery Prince Sultan Military Medical City

Tools of the Gastroenterologist: Introduction to GI Endoscopy

Charles Mulligan, MD, FACS, FCCP 26 March 2015

Vesalius SCALpel : Esophagus (see also: esophageal folios) Anatomy/physiology

42 yr old male with h/o Graves disease and prior I 131 treatment presents with hyperthyroidism and undetectable TSH. 2 hr uptake 20%, 24 hr uptake 50%

Small Intestine. Protocol revision date: January 2005 Based on AJCC/UICC TNM, 6 th edition

Bronchogenic Carcinoma

objectives Pitfalls and Pearls in PET/CT imaging Kevin Robinson, DO Assistant Professor Department of Radiology Michigan State University

Esophageal and GEJ Cancers. Case Presentations

Case Scenario 1. 7/13/12 Anterior floor of mouth biopsy: Infiltrating squamous cell carcinoma, not completely excised.

[A RESEARCH COORDINATOR S GUIDE]

Take Home Quiz 1 Please complete the quiz below prior to the session. Use the Multiple Primary and Histology Rules

The present staging system for esophageal carcinoma

Anatomy: From cricoid cartilage to diaphragm 25 Cms. 4 portions: Cervical 5 cms. Thoracic 25 cms. Abdominal 2 cms. Blood supply Lymphatic spread

Barrett s Esophagus. Abdul Sami Khan, M.D. Gastroenterologist Aurora Healthcare Burlington, Elkhorn, Lake Geneva, WI

Case Scenario 1. The patient agreed to a CT guided biopsy of the left upper lobe mass. This was performed and confirmed non-small cell carcinoma.

Staging Challenges in Lower GI Cancers. Disclosure of Relevant Financial Relationships. AJCC 8 th edition and CAP protocol updates

Transcription:

RTC Dec 11 2009 Felicitas Koller and Eric Grogan

Cancer Statistics, United States Number of patients 200000 150000 100000 50000 0 Lung Breast New Cases Deaths Esophageal Colorectal Prostate http://www.cancer.org/statistics Histology

Squamous Cell Worldwide >>> < Men vs. Women Age Disease Association Location Adenocarcinoma 3:1 (fifth decade) 15:1 (fifth decade) Rarely <30; mortality greatest in men 60 70 Exposure to environmental factors; smoking, ETOH, pickled/smoked; deficiencies; tylosis, Plummer Vinson syndrome; end stage achalasia Squamous tissue in upper and middle third Rarely < 40, incidence increases with age Barrett s 40 fold increase Submucosal glands of esophagus; heterotopic islands of columnar epithelium; malignant degeneration of metaplastic columnar epithelium Survival 70% with polypoid; 15% advanced Nature Sensitive to chemotherapy Embedded in Barrett's esophagus, less sensitive to chemotherapy

Commences at C6 joins stomach at T11, usually 25 30 cm long. 2.5 cm in diameter Structures: distance from incisors 13 cm cricopharyngeus 22 cm azygous vein 22 27cm carina 40 cm EG junction

The Layers at?? The esophagus lacks a serosa: mucosa, submucosa and muscularis propria Two interconnecting lymphatic plexuses arising from the submucosa and muscularis layers.

GE junction at?? Endoscopically: The squamocolumnar epithelial junction (Zline) The transition from the smooth esophageal lining to the rugal folds of the stomach Externally: The collar of Helvetius (or loop of Willis) The gastroesophageal fat pad are consistent identifiers of the GEJ

Case Presentation 3/24/09 CC: 73 yo man with a 2 month history of progressive difficulty with swallowing. Solid foods pass the upper esophagus with some difficulty. Has no lodging, but has to drink more water No hx of esophagitis or stricture HTN, HLD, BPH, hx. of arrhythmia PSH: Anterior neck fusion WHAT ADDITIONAL HISTORY? Smoking, drinking, anemia, GERD or GERD sx, foul breath, regurgitation of food, hx of chemical or radiation exposure, medications DIFFERENTIAL DX? Obstructive lesions: tumors, inflammatory masses; Zenker's diverticulum, esophageal webs mediastinal masses,cervical spondylosis, radiation, chemical or medication induced; Schatzki's Ring, vascular compression, enlarged aorta or left atrium, aberrant vessels, lymphadenopathy, substernal thyroid Neuromuscular disorders: achalasia; DES, Hypertensive LES, nutcracker esophagus, scleroderma INITIAL TEST? Barium Swallow Why? both functional and anatomic.

A B C D

1. A=nutcracker esophagus, B=cancer C=achalasia, D= cancer 2. A=Schatzki s ring, B=cancer, C=normal, D=Barrett s esophagus 3. A=reflux, B=compression from mediastinal mass, C= normal, D=achalasia 4. A=diffuse esophageal spasm, B=Zenker s diverticulum, c=normal, d=cancer

EGD with biopsy tissue 1. Location (w/ respect to incisors) 2. Nature of the lesion 3. Proximal and distal extent of the lesion 4. Relationship of the lesion to the cricop., GEJ, cardia 5. Distensibility of the stomach CT scan thorax length of the tumor, thickness of the esophagus and stomach, lymph node status and distant disease to the liver and lungs PET scan primary mass, regional lymph nodes and distant disease Esophageal ultrasound depth of the tumor, the length of the tumor, the degree of luminal compromise, the status of regional lymph nodes, and involvement of adjacent structures

EGD: 6 7 mm, 3cm long, 28 cm from the incisors. Patchy antral erythema, normal duodenum Pathology: invasive moderately differentiated squamous cell carcinoma, vascular invasion CT: focal mid esophageal wall thickening, no adenopathy PET: intense focal FDG activity in the mid thoracic esophagus immediately posterior to the left mainstem bronchus. 3 FDG avid nodules: r of midline at the same level, subcarinal and right paratracheal

1 ST hyperechoic (white), represents the superficial mucosa (epithelium and lamina propria). 2 nd hypoechoic (black), represents the deep mucosa (muscularis mucosa). 3 rd hyperechoic (white), represents the submucosa. 4 th hypoechoic (black), represents the muscularis propria. 5 th hyperechoic (white) is the periesophageal tissue.

A, A T1 lesion is observed as a hypoechoic thickening of the mucosal layer adjacent to the normal appearing wall pattern; B, a T2 lesion is seen as a hypoechoic mass invading into but not through the muscularis propria

T2 N1 by EUS What s his stage What are his treatment options

Tumor Nodes Metastasis TX: Primary tumor cannot be assessed NX: Regional lymph nodes cannot be assessed MX: Distant metastasis cannot be assessed T0: No evidence of primary tumor N0: No regional lymph node metastasis M0: No distant metastasis Tis: Carcinoma in situ N1: Regional lymph node metastasis M1: Distant metastasis Tumors of the lower thoracic esophagus: M1a: Metastasis in celiac lymph nodes M1b: Other distant metastasis Tumors of the midthoracic esophagus: M1a: Not applicable M1b: Nonregional lymph nodes and/or other distant metastasis Tumors of the upper thoracic esophagus: M1a: Metastasis in cervical nodes M1b: Other distant metastasis T1: Tumor invades lamina propria or submucosa T2: Tumor invades muscularis propria T3: Tumor invades adventitia T4: Tumor invades adjacent structures

Stage 0 Stage 1 Stage 2 Stage 3 Stage 4 Tis, N0, M0 T1, N0, M0 Stage IIA T2, N0, M0 T3, N0, M0 T3, N1, M0 T4, any N, Any T, any N, M1 Stage IIB T1, N1, M0 T2, N1, M0 Stage IVA Any T, any N, M1a Stage IVB Any T, any N, M1b

1. Surgery alone 2. Surgery adjuvant chemo 3. Chemoradiation alone 4. Neoadjuvant chemoradiation and then surgery

Case Presentation 4/2009 6/2009 Patient receives neoadjuvant chemotherapy (cisplatin and capecitibine) as well as radiotherapy. Repeat PET imaging shows : 1.Decreased LN size with loss of FDG activity. 2.In the middle esophagus right below the carina, moderate FDG activity is seen associated with residual esophageal wall thickness. On previous scan, this was primary site of the cancer with intense FDG uptake and significant esophageal wall thickness. EGD: 1.UES was located at 19 cm from insertion, and the GE junction was located at 41 cm from insertion. 2.31 cm from insertion there was a partially circumferential superficial ulcer with scar tissue. There were proximal esophageal plaques consistent with candidal esophagitis. There was no Barrett's. Stomach: normal Duodenum: normal

Transhiatal Transthoracic (Ivor Lewis) Three field (McKeown) Minimally invasive

Approach / Incisions Transhiatal Transthoracic Minimally invasive Conduit Stomach Colon Jejunum, supercharged Other Anastamosis Neck Chest Route Posterior mediastinum Retrosternal Subcutaneous

Case Presentation JI underwent operation 7/28/09: 1. Bronchoscopy. 2. Esophagogastroduodenoscopy. 3. Laparotomy with transthoracic esophagectomy. 4. Jejunostomy feeding tube. 5. Ligation of thoracic duct. 6. Pyloroplasty Pathology: 1) ESOPHAGUS AND STOMACH, DISTAL ESOPHAGECTOMY: LIMITED RESIDUAL SQUAMOUS CELL CARCINOMA, DISTAL ESOPHAGUS, IN SUBMUCOSA AND MUSCULARIS PROPRIA, 1.8 MM IN GREATEST EXTENT; PRESENT IN A BACKGROUND OF SEVERE MUCOSAL AND SUBMUCOSAL ULCERATION; ALL SURGICAL MARGINS WIDELY FREE OF CARCINOMA; TWO LYMPH NODES NEGATIVE FOR MALIGNANCY (0/2), (SEE COMMENT). 2) LYMPH NODES, LEVEL 7, EXCISION: 3 LYMPH NODES NEGATIVE FOR MALIGNANCY (0/3). COMMENT: These findings correspond to AJCC pathologic stage yiia (ypt2n0m n/a).

No difference in operative time, blood loss, morbidity or mortality Survival similar Anastomotic Leak rate Cervical 11% Thoracic 6% Putnam et al., Ann Thor Surg,, 1994

Identified endoscopically Resection, mediastinal debridement Diversion, delayed reconstruction 50% mortality

Smoking cessation Enteral nutrition in pts undergoing induction tx Epidural anesthesia Bronchopulmonary hygiene Early extubation No difference between TTE and THE

Incidence 1 3% (TTE=THE) Suspected with high continued CT output Pleural triglycerides, lymphocytes, chylomicrons Most will not close with conservative management

Non operative stratagies NPO, TPN ±octreotide MCT diet ± octreotide IR embolization of thoracic duct Operative ligation VATS vs. open